India's Healthcare Boom Has a Cash Problem Nobody's Talking About
How OmniCard's Business Fintech OS closes the gap
₹8.1 lakh crore is stuck in unpaid invoices across India right now. A slice of it is sitting inside a hospital's ward float, a pharma plant's vendor ledger, or a diagnostics chain's cash drawer — and nobody's counted it yet.
A 12-facility hospital chain closes its quarter 22% over budget on petty cash alone, and no one can say exactly why. Four hospitals report float updates over WhatsApp. Two units still run shared Excel sheets nobody updates on time. One unit head is still "compiling the numbers." By the time finance stitches it all together, the number on the board slide is already three weeks stale.
This isn't a one-off. Ask any CEO or CFO running a multi-hospital chain, a pharma manufacturer, or a diagnostics network in India, and they'll tell you a version of the same story: growth is outrunning finance's ability to see it, let alone control it.
India's healthcare sector is valued at roughly ₹32 lakh crore ($372 billion) and is on track to cross ₹54 lakh crore ($638 billion) within the next couple of years, growing at a CAGR of around 17.5–22.5%. Hospitals and clinics alone command close to 40% of that market, with the hospital segment projected to nearly double from $98.98 billion in 2023 to $193.59 billion by 2032. Pharma is climbing just as fast — from a $50 billion industry toward $130 billion by 2030 — while healthcare demand in Tier 2 and Tier 3 cities is growing even quicker than in the metros.
New hospital wings, new pharma plants, new diagnostic labs, and new pharmacy outlets are the headline on every CEO's growth story. But every new facility, every new nursing station, every new distributor and every new contract-staffing vendor is another field of financial exposure that finance has to track, reconcile, and defend in an audit — often with the same headcount and the same spreadsheets it had three years ago. This is the gap OmniCard, India's AI-powered Business Fintech OS, was built to close — and it's why the platform is increasingly the finance layer of choice for hospital CFOs, pharma controllers, and diagnostics finance heads who've done chasing spreadsheets.
A sector CEOs are scaling faster than CFOs can control
A few numbers explain why finance teams in this sector are under so much pressure.
Capacity is expanding across every format. Hospital chains, pharma manufacturers, diagnostics networks, and pharmacy retail are all in active capacity-addition mode, backed by consolidation and rising private-equity investment — Q3 2025 alone saw 72 deals worth $3.5 billion across pharma, hospital, and biotech. Every new bed, every new plant line, every new lab and every new outlet is a fresh set of bank accounts, floats, and vendor relationships a CFO has to bring under control from day one.
Felt most by: CEOs, CFOs, and finance controllers commissioning new facilities.
The vendor base — distributors, reagent suppliers, biomedical vendors — is enormous and thinly documented. Hospitals and pharma companies run on thousands of small vendors: local pharmacy distributors, reagent and consumable suppliers, ambulance and courier fleets, housekeeping and biomedical service contractors. As chains expand into Tier 2 and Tier 3 cities — growing 16–18% CAGR, faster than metros — CFOs inherit exactly the cash-heavy, thinly-documented financial habits that are hardest to formalise across thousands of small vendors.
Felt most by: Procurement heads and CFOs managing distributor and supplier networks.
Delayed payments and reimbursement cycles are a structural, sector-wide drag on working capital. An estimated ₹8.1 lakh crore is currently locked up in delayed payments to MSME suppliers nationally, and the average small supplier now carries close to ₹3.8 crore in receivables overdue beyond a year, with the national invoice cycle stretching to roughly 73 days despite a regulatory 45-day mandate. For hospital and pharma CFOs, that delay compounds with insurance TPA settlement cycles and government scheme reimbursement lags — every slipped supplier payment is a day of strained vendor relationships and disrupted drug or consumable supply.
Felt most by: CFOs and finance teams managing supplier and payer relationships.
Multi-format, multi-site operating models are the default. Healthcare groups run owned hospitals, leased diagnostic centres, franchised pharmacy outlets, and third-party contract manufacturing side by side, each with its own procurement, payroll, and reconciliation logic — and head office is expected to see through all of it in real time to plan capex, capacity, and working capital.
Felt most by: Group CFOs and plant/unit controllers across formats.
For a CEO, this is a growth story. For a CFO, a plant controller, or a compliance officer, it's a scaling-risk story — and it's exactly where OmniCard's Business Fintech OS steps in.
7 financial blind spots — and who in the organisation feels each one
1. Ward-level and OPD petty cash is untracked.
Felt most by: Nursing superintendents, ward managers, and finance controllers.
Consumable top-ups, minor equipment repairs, patient-welfare advances, and OPD cash float are notoriously hard to monitor from head office — and untracked ward-level cash is the easiest line item for an auditor to flag. OmniCard's Corporate Cards (RuPay) let CFOs issue department-level cards with hard spend limits — pharmacy, housekeeping, biomedical, patient welfare — so every rupee is attributed to a cost centre before it's spent, not reconstructed after the fact.
2. Multi-hospital and multi-plant groups lack consolidated visibility.
Felt most by: CEOs and CFOs.
When a group runs hospitals, labs, and plants across five, ten, or thirty locations, no CEO should have to wait a week for consolidated spend numbers, and no CFO should have to stitch together spreadsheets from every unit controller to get there. OmniCard's unified dashboard gives finance leadership one real-time view across every facility — the kind of visibility a growth-stage healthcare group needs to make capex and bed-expansion calls with confidence.
3. Field medical reps, biomedical service engineers, and pharmacy-visit teams travel with no verified spend-to-visit link.
Felt most by: MR and sales heads, biomedical service teams, and the finance teams approving their claims.
Medical representatives covering hundreds of doctors and chemists, biomedical engineers servicing equipment across hospitals, and field staff visiting distributors and pharmacy outlets are a chronic weak spot for reconciling expense claims against actual visits. OmniCard's Motion brings GPS-based field-force tracking, so finance professionals are approving spend against verified visit data, not paperwork alone.
4. Raw-material, API, and consumable vendor payouts are cash-heavy, slow, and chronically delayed.
Felt most by: CFOs and procurement leads managing pharma and hospital supplier relationships.
With an estimated ₹8.1 lakh crore locked in delayed MSME payments nationally and invoice cycles stretching to around 73 days against a 45-day mandate, slow vendor settlement is one of the biggest working-capital and supply-continuity risks a pharma manufacturer or hospital procurement team carries. OmniCard's B2B UPI enables instant, fully trackable payouts to API, reagent, consumable, and packaging suppliers — replacing float-heavy cash and cheque cycles with same-day, auditable settlement that protects supplier relationships and keeps production and patient care running.
5. Inbound and outbound logistics spend — cold-chain, ambulance fleet, sample pickup, and distribution — is fragmented across carriers.
Felt most by: Supply chain and logistics heads, and finance teams reconciling freight costs.
Cold-chain inbound movement of API and vaccines, ambulance and patient-transfer fleets, and sample-pickup and last-mile pharmacy delivery run on a mix of owned fleets, third-party transporters, and last-mile riders, each generating its own toll receipts, fuel bills, and driver cash advances that are painful to consolidate. OmniCard's FASTag Management and iFleet Pay bring toll and fleet spend onto a single trackable rail, giving logistics and finance heads one clean view of per-trip and per-route cost instead of a pile of disconnected receipts.
6. Nursing staff, contract lab technician, and housekeeping-crew reimbursements are manual and delayed.
Felt most by: HR leaders and finance operations teams.
Manual reimbursement queues for duty travel, night-shift allowances, and contract-staff advances are a genuine retention issue in a sector already competing hard for skilled nursing and technician talent — and they consume disproportionate finance-team bandwidth. OmniCard's Reimburse360 automates the claim-to-payout cycle, cutting settlement time from weeks to days.
7. Compliance and audit trails are weak on capex, biomedical equipment, and drug procurement spend.
Felt most by: CFOs, compliance officers, and internal auditors.
Healthcare is a capex-intensive, tightly regulated sector — GST input-credit implications on every equipment purchase, NPPA/DPCO pricing compliance on drug procurement, and job-work vendor payments make these some of the hardest categories to defend during an audit. OmniCard's AI-powered categorisation tags and classifies every transaction automatically, giving compliance officers a continuous, audit-ready trail instead of a year-end scramble.
What this means if you sit in the CEO's or CFO's chair
If you're a CEO, the calculus is simple: every bed you add, every plant line you commission, or every new outlet you open should come with financial visibility on day one, not six months into onboarding a new finance hire. If you're a CFO, controller, or compliance officer, the calculus is even more direct — you're the one who has to answer for every untracked rupee and every delayed supplier payment when the auditors, or the vendors, come calling.
OmniCard is built for exactly this seat. It's an RBI-licensed PPI issuer that has already processed ₹3,400 Cr+ in payments for 1,000+ enterprise clients across 700+ cities, giving healthcare CFOs and finance professionals a proven, enterprise-scale operating layer, not a point solution bolted onto legacy banking rails.
As India's healthcare sector keeps expanding under capacity addition, Tier 2/3 city growth, and consolidation, the CEOs and CFOs who win won't just be the ones with the most beds, plants, or outlets — they'll be the ones whose finance teams can see, control, and audit every vendor and pay every rupee on time — and in real time. That's what a Business Fintech OS is for.
Sources: Mordor Intelligence, IBEF, Bajaj Finance, Nexdigm, InsightRx, MarkNtel Advisors, 6Wresearch, Recordent Indian SME Receivables Report 2026, KNN India.
